Day One Biopharmaceutical... (DAWN)
Day One Biopharmaceuticals Statistics
Share Statistics
Day One Biopharmaceuticals has 101.36M shares outstanding. The number of shares has increased by 15.4% in one year.
| Shares Outstanding | 101.36M |
| Shares Change (YoY) | 15.4% |
| Shares Change (QoQ) | 14.91% |
| Owned by Institutions (%) | 97.02% |
| Shares Floating | 74.28M |
| Failed to Deliver (FTD) Shares | 151 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 16.6M, so 16.46% of the outstanding shares have been sold short.
| Short Interest | 16.6M |
| Short % of Shares Out | 16.46% |
| Short % of Float | 22.84% |
| Short Ratio (days to cover) | 15.11 |
Valuation Ratios
The PE ratio is -12.42 and the forward PE ratio is -11.55. Day One Biopharmaceuticals's PEG ratio is 0.22.
| PE Ratio | -12.42 |
| Forward PE | -11.55 |
| PS Ratio | 9.04 |
| Forward PS | 1.2 |
| PB Ratio | 2.36 |
| P/FCF Ratio | -14.78 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Day One Biopharmaceuticals Inc. has an Enterprise Value (EV) of 934.31M.
| EV / Earnings | -9.78 |
| EV / Sales | 7.12 |
| EV / EBITDA | -4.3 |
| EV / EBIT | -4.3 |
| EV / FCF | -11.64 |
Financial Position
The company has a current ratio of 7.66, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.66 |
| Quick Ratio | 7.61 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.51 |
| Cash Flow / Debt | -30.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.19% and return on capital (ROIC) is -39.52%.
| Return on Equity (ROE) | -0.19% |
| Return on Assets (ROA) | -0.16% |
| Return on Capital (ROIC) | -39.52% |
| Revenue Per Employee | $724,646.41 |
| Profits Per Employee | $-527,602.21 |
| Employee Count | 181 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.59 |
Taxes
| Income Tax | -7.14M |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by -48.58% in the last 52 weeks. The beta is -1.39, so Day One Biopharmaceuticals's price volatility has been lower than the market average.
| Beta | -1.39 |
| 52-Week Price Change | -48.58% |
| 50-Day Moving Average | 10.73 |
| 200-Day Moving Average | 13.11 |
| Relative Strength Index (RSI) | 36.09 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, Day One Biopharmaceuticals had revenue of 131.16M and earned -95.5M in profits. Earnings per share was -1.02.
| Revenue | 131.16M |
| Gross Profit | 125.88M |
| Operating Income | -217.27M |
| Net Income | -95.5M |
| EBITDA | -217.27M |
| EBIT | -217.27M |
| Earnings Per Share (EPS) | -1.02 |
Balance Sheet
The company has 124.97M in cash and 2.6M in debt, giving a net cash position of 122.37M.
| Cash & Cash Equivalents | 124.97M |
| Total Debt | 2.6M |
| Net Cash | 122.37M |
| Retained Earnings | -554.08M |
| Total Assets | 582.79M |
| Working Capital | 488.88M |
Cash Flow
In the last 12 months, operating cash flow was -78.11M and capital expenditures -2.17M, giving a free cash flow of -80.28M.
| Operating Cash Flow | -78.11M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | -80.28M |
| FCF Per Share | -0.86 |
Margins
Gross margin is 95.98%, with operating and profit margins of -165.65% and -72.81%.
| Gross Margin | 95.98% |
| Operating Margin | -165.65% |
| Pretax Margin | -67.36% |
| Profit Margin | -72.81% |
| EBITDA Margin | -165.65% |
| EBIT Margin | -165.65% |
| FCF Margin | -61.21% |
Dividends & Yields
DAWN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.56% |
| FCF Yield | -9.75% |
Analyst Forecast
The average price target for DAWN is $32, which is 294.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 294.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 4.78 |
| Piotroski F-Score | 3 |